Campbell & CO Investment Adviser LLC Has $293,000 Stake in Biogen Inc. $BIIB

Campbell & CO Investment Adviser LLC trimmed its stake in Biogen Inc. (NASDAQ:BIIB) by 69.0% in the third quarter, Holdings Channel.com reports. The firm owned 2,094 shares of the biotechnology company’s stock after selling 4,666 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in Biogen were worth $293,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. TD Private Client Wealth LLC increased its position in Biogen by 22.5% during the third quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock worth $58,000 after buying an additional 76 shares during the last quarter. CX Institutional boosted its stake in shares of Biogen by 6.1% during the 3rd quarter. CX Institutional now owns 1,453 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 83 shares in the last quarter. Rothschild Investment LLC increased its holdings in shares of Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 88 shares during the last quarter. True Wealth Design LLC increased its holdings in shares of Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 90 shares during the last quarter. Finally, Legacy Wealth Asset Management LLC raised its stake in shares of Biogen by 3.8% in the 2nd quarter. Legacy Wealth Asset Management LLC now owns 2,511 shares of the biotechnology company’s stock valued at $315,000 after acquiring an additional 91 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Stock Performance

NASDAQ:BIIB opened at $171.59 on Friday. The firm has a market capitalization of $25.17 billion, a PE ratio of 15.64, a price-to-earnings-growth ratio of 1.44 and a beta of 0.13. The company has a quick ratio of 2.04, a current ratio of 2.72 and a debt-to-equity ratio of 0.35. Biogen Inc. has a 12-month low of $110.04 and a 12-month high of $190.20. The firm has a 50-day moving average price of $175.80 and a 200 day moving average price of $153.17.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.89 by $0.92. Biogen had a return on equity of 14.13% and a net margin of 15.98%.The company had revenue of $2.53 billion for the quarter, compared to the consensus estimate of $2.34 billion. During the same period in the previous year, the business earned $4.08 earnings per share. The company’s quarterly revenue was up 2.8% on a year-over-year basis. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Research analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on BIIB shares. Sanford C. Bernstein upped their target price on Biogen from $157.00 to $197.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. Royal Bank Of Canada restated an “outperform” rating on shares of Biogen in a research note on Tuesday, January 13th. Truist Financial raised their target price on shares of Biogen from $142.00 to $190.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. BMO Capital Markets lifted their target price on shares of Biogen from $150.00 to $165.00 and gave the stock a “market perform” rating in a report on Thursday, December 18th. Finally, Mizuho boosted their target price on shares of Biogen from $177.00 to $207.00 and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Ten equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Biogen presently has an average rating of “Hold” and a consensus price target of $191.85.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.